Sign in to continue:

Friday, March 20th, 2026

Quantum Cyber Aligns With Trump Administration’s National Cybersecurity Strategy, Targets Acquisitions in Quantum and Cyber Defense Sectors 1





Quantum Cyber Aligns with National Cybersecurity Strategy and Pursues Strategic Acquisitions

Quantum Cyber Aligns Strategy with Trump Administration’s National Cybersecurity Framework, Targets Acquisitions in Quantum and Cyber Defense Sectors

Key Highlights for Investors

  • Quantum Cyber (Mainz Biomed N.V., NASDAQ: QUCY) announces a major strategic update in response to the Trump Administration’s newly released National Cybersecurity Strategy.
  • Company is actively evaluating multiple strategic acquisition opportunities in the quantum computing and cyber defense sectors to capitalize on the new federal policy direction.
  • Lead shareholder David Lazar has pre-funded an additional \$3 million investment tranche, bringing his total investment to \$6 million.
  • The Trump Administration’s strategy signals a significant expansion in investment and regulatory focus for cybersecurity and quantum computing, directly validating Quantum Cyber’s business thesis.
  • The company’s acquisition pipeline includes targets in quantum computing, post-quantum cryptography, zero-trust architecture, and related cybersecurity disciplines.
  • Completion of the second investment tranche is subject to shareholder approval and other customary closing conditions.

Strategic Update: Aligning with National Cybersecurity Priorities

On March 10, 2026, the White House, under the direction of President Donald Trump, released a comprehensive National Cybersecurity Strategy. This strategy outlines six foundational pillars aimed at defending U.S. interests in cyberspace, including:

  • Proactive detection and defeat of adversarial cyber actors before network breaches occur
  • Streamlining cyber regulations to reduce compliance burdens and synchronize private sector efforts with government objectives
  • Accelerated adoption of post-quantum cryptography, zero-trust architecture, and secure cloud infrastructure across national security systems
  • Prioritization of U.S.-developed technologies over adversarial products
  • Development of a robust domestic cyber workforce
  • Promotion of cryptocurrency and blockchain security through post-quantum cryptographic standards

Quantum Cyber’s management sees this federal strategy as direct validation of its focus on quantum computing and cybersecurity—two areas now deemed critical national priorities.

Acquisition Strategy: Building a Platform for Growth

In response to the policy shift, Quantum Cyber’s management is actively evaluating a pipeline of strategic acquisition candidates. These targets operate in quantum computing, post-quantum cryptography, zero-trust network architecture, and adjacent cybersecurity disciplines. The company believes that a targeted acquisition approach will accelerate the development of an operationally active platform with measurable revenue potential, directly aligned with U.S. national security priorities.

The company is currently conducting preliminary due diligence and engaging in discussions with multiple potential targets. While no definitive agreements have yet been reached, management expresses cautious optimism about both the quality of the pipeline and the timeliness of this strategic opportunity created by the current federal policy environment.

“The Trump Administration’s cybersecurity strategy is a landmark policy commitment that confirms what we have long believed: quantum and cyber defense are the defining technology frontiers of our generation. We are actively looking at several acquisition opportunities that we believe would position Quantum Cyber as a meaningful participant in the sectors the White House has identified as critical national priorities. We look forward to sharing more details with our shareholders in due course.”

Financial Update: Shareholder David Lazar Pre-Funds Additional Tranche

In a significant show of confidence, lead shareholder David Lazar has pre-funded the second tranche of a previously announced private placement, adding \$3 million and bringing his total investment to \$6 million. The completion of the second tranche and the issuance of Series D and Series E preferred stock are subject to customary closing conditions, including shareholder approval.

The company’s management expressed gratitude for Mr. Lazar’s continued support, viewing his additional investment as a strong endorsement of Quantum Cyber’s strategic direction and the significant opportunities in quantum and cybersecurity sectors.

Important Information for Shareholders

  • The company’s acquisition strategy, if successful, could position Quantum Cyber as a significant player in quantum and cyber defense, potentially impacting future revenues and share value.
  • Completion of the next investment tranche and related share issuances are subject to shareholder approval, which may affect capital structure and ownership dilution.
  • There is no guarantee that any acquisition will be consummated, or that the company will achieve its strategic objectives.
  • Federal policy alignment and increased investor funding highlight potential catalysts for future share price movement, but risks remain as outlined in the company’s forward-looking statements.

About Quantum Cyber

Quantum Cyber (Mainz Biomed N.V., NASDAQ: QUCY) is a publicly traded company focused on building a diversified platform at the intersection of quantum computing and cybersecurity. The company pursues strategic acquisitions and partnerships in post-quantum cryptography, zero-trust architecture, and related national security technology sectors.

Forward-Looking Statements Disclaimer

This article contains forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those indicated due to a variety of factors, including the successful completion of acquisitions, regulatory changes, shareholder approval of investment tranches, and other risks described in the company’s public filings with the SEC. Investors should not place undue reliance on forward-looking statements and are encouraged to review all company disclosures and filings. This article does not constitute an offer to sell or the solicitation of an offer to buy securities.




View MAINZ BIOMED N.V. Historical chart here



   Ad